Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan
Abstract
To elucidate the host genetic loci affecting severity of SARS-CoV-2 infection, or Coronavirus disease 2019 (COVID-19), is an emerging issue in the face of the current devastating pandemic. Here, we report a genome-wide association study (GWAS) of COVID-19 in a Japanese population led by the Japan COVID-19 Task Force, as one of the initial discovery GWAS studies performed on a non-European population. Enrolling a total of 2,393 cases and 3,289 controls, we not only replicated previously reported COVID-19 risk variants (e.g., LZTFL1, FOXP4, ABO, and IFNAR2), but also found a variant on 5q35 (rs60200309-A at DOCK2) that was associated with severe COVID-19 in younger (<65 years of age) patients with a genome-wide significant p-value of 1.2 × 10-8 (odds ratio = 2.01, 95% confidence interval = 1.58-2.55). This risk allele was prevalent in East Asians, including Japanese (minor allele frequency [MAF] = 0.097), but rarely found in Europeans. Cross-population Mendelian randomization analysis made a causal inference of a number of complex human traits on COVID-19. In particular, obesity had a significant impact on severe COVID-19. The presence of the population-specific risk allele underscores the need of non-European studies of COVID-19 host genetics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by AMED, JST CREST, MHLW, Takeda Science Foundation, the Mitsubishi Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the participants provided written informed consent as approved by the ethical committees of Keio University School of Medicine, Osaka University Graduate School of Medicine, and affiliated institutes.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵158 These authors jointly supervised the study.
Data Availability
GWAS summary statistics of the study will be publicly available.
Subject Area
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (200)
- Cardiovascular Medicine (2915)
- Dermatology (249)
- Emergency Medicine (438)
- Epidemiology (12707)
- Forensic Medicine (12)
- Gastroenterology (826)
- Genetic and Genomic Medicine (4565)
- Geriatric Medicine (414)
- Health Economics (726)
- Health Informatics (2912)
- Health Policy (1068)
- Hematology (385)
- HIV/AIDS (921)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4329)
- Nursing (234)
- Nutrition (636)
- Oncology (2261)
- Ophthalmology (643)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (278)
- Palliative Medicine (83)
- Pathology (497)
- Pediatrics (1196)
- Primary Care Research (494)
- Public and Global Health (6913)
- Radiology and Imaging (1524)
- Respiratory Medicine (915)
- Rheumatology (436)
- Sports Medicine (382)
- Surgery (484)
- Toxicology (60)
- Transplantation (210)
- Urology (178)